Optimum Therapeutics, LLC

Carlsbad, CA

UEI
CAAGN783MMF1
CAGE
4FHQ8
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Woman Owned Business
  • Asian-Pacific American Owned
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
Other NAICS codes in SAM.gov
SAM.gov registration date
Physical address
1815 Aston Ave #107, Carlsbad, CA 92008, USA
Website
optimumtx.com
Founded
2000
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Combination chemo-sirna gene therapy of nonmuscle-invading bladder cancer R43TR000356 National Institutes of Health $344,460
Targeting multiple signaling steps to achieve synergy R01CA163015 National Cancer Institute (NIH) $1,915,391
Synergistic chemo-sirna combination therapy R01CA158300 National Cancer Institute (NIH) $1,828,892
Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder CA R43CA162448 National Institutes of Health $303,226
Multiscale computational models for developing combination cancer therapy R01GM100487 National Institute of General Medical Sciences (NIH) $1,287,325

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Optimum Therapeutics, LLC registered in SAM.gov?

Yes. Optimum Therapeutics, LLC's SAM.gov registration is active through October 22, 2026.

What is Optimum Therapeutics, LLC's most recent federal award?

Optimum Therapeutics, LLC's most recent federal grant award is Combination chemo-sirna gene therapy of nonmuscle-invading bladder cancer (R43TR000356), from National Institutes of Health, on September 8, 2012.

On GovTribe

See Optimum Therapeutics, LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login